LLY
Eli Lilly and Company
LLY has the edge over SHC overall, supported by stronger fundamentals and stronger modeled upside.
SHC
Sotera Health Company
SHC offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Weak |
SHC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $16.30 | — |
| Current | 27x | $16.30 | — |
| Cheap | 38x | $23.00 | +41% |
| Fair | 61x | $36.40 | +123% |
| Expensive | 173x | $104 | +538% |
Historical ranges are pointers, not guarantees.
SHC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for SHC, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SHC on earnings, with more consistent year-over-year improvement.
SHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.04 | +73% |
| Q3 2026 | $0.60 | +200% |
| Q2 2026 | $0.57 | +533% |
| Q1 2026 | $0.41 | +356% |
| Q4 2025 | $0.27 | +69% |
| Q3 2025 | $0.20 | -20% |
| Q2 2025 | $0.09 | -36% |
| Q1 2025 | $0.09 | -53% |
| Q4 2024 | $0.16 | -11% |
SHC earned $0.60 per share over the past year, about three times what it earned the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SHC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SHC on profitability, with a higher operating margin.
SHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $324.9M | +4.4% |
| Q2 2026 | $321.4M | +9.2% |
| Q1 2026 | $280M | +10% |
| Q4 2025 | $303.4M | +4.6% |
| Q3 2025 | $311.3M | +9.1% |
| Q2 2025 | $294.3M | +6.4% |
| Q1 2025 | $254.5M | +2.6% |
| Q4 2024 | $290.2M | -6.5% |
SHC's revenue has grown year over year for seven quarters in a row: $325M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | +2.3 points |
| Q2 2026 | 24% | +18 points |
| Q1 2026 | 15% | +21 points |
| Q4 2025 | 23% | -6.8 points |
| Q3 2025 | 23% | -4.8 points |
| Q2 2025 | 6.4% | -21 points |
| Q1 2025 | -5.8% | -27 points |
| Q4 2024 | 30% | -3.5 points |
SHC's operating margin was 26% last quarter, up 2.3 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SHC on cash flow, with more consistent year-over-year improvement.
SHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57.7M | +65% |
| Q2 2026 | $42M | +61% |
| Q1 2026 | -$16.7M | -147% |
| Q4 2025 | $52.4M | +$62.6M |
| Q3 2025 | $35M | -43% |
| Q2 2025 | $26.2M | +35% |
| Q1 2025 | $35.6M | +$60.8M |
| Q4 2024 | -$10.2M | -121% |
SHC generated $135M in free cash flow over the past year, up 56% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +2.9% | +8.1M shares |
| 5 years | +3.5% | +9.7M shares |
| Available history | +3.7% | +10.4M shares |
SHC has 289M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over SHC on leverage, with a lower net debt burden relative to earnings.
SHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 4.6x | High |
| Q1 2026 | 5.5x | High |
| Q4 2025 | 6.3x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 5.7x | High |
| Q1 2025 | 4.9x | High |
| Q4 2024 | 4.2x | High |
SHC's net debt is about 4.3 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 20.9 | Neutral |
SHC's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SHC PE vs Healthcare Sector
| Metric | SHC | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 5.1% above |
| PE % | 8 | 34 | 26 pts below |
SHC has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SHC on trend strength, trading above more of its moving averages.
SHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.6 | 7.5% below |
| 20 week MA | $18.2 | 10% below |
| 50 week MA | $17.1 | 4.4% below |
| 100 week MA | $15.3 | 6.7% above |
| 200 week MA | $15.1 | 7.9% above |
SHC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 7.9% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SHC on returns for 2026, with the stronger performance.
SHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.1 | $26.9 | +7.3% |
| 2021 | $26.9 | $23.6 | -13% |
| 2022 | $23.6 | $7.93 | -66% |
| 2023 | $7.93 | $16.9 | +112% |
| 2024 | $16.9 | $13.5 | -20% |
| 2025 | $13.5 | $17.7 | +31% |
| 2026 YTD | $17.7 | $16.3 | -7.9% |
SHC's yearly returns have swung widely, from +112% in 2023 to −66% in 2022. It's down 7.9% so far in 2026.